Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent influenza vaccine. The subjects will be randomized at a 1:1:1 ratio.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

NCT02247362

Influenza

UNKNOWN PHASE1/PHASE2

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494

Influenza

UNKNOWN PHASE1

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

NCT02307851

Influenza

COMPLETED PHASE2

Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

NCT05734040

Influenza

COMPLETED PHASE2

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811

Influenza Infection

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either VAX2012Q or Fluzone. Four hundred fifty (450) subjects will be randomized 1:1:1 ratio of either 8 or 12 mcg VAX2012Q dose levels or to Fluzone® Quadrivalent vaccine.

Randomization will be stratified for age (18-49 and 50-64 years). Subjects will be stratified by two age groups (18-49 and 50-64) and randomized in a 1:1:1 ratio to either 8 or 12 mcg VAX2012Q dose levels or to Fluzone® Quadrivalent vaccine. 25-35% of the total study population will be recruited into the 50-64 age group.

The primary objective of the study is to evaluate the seroconversion rates at Day 21 for both dose levels of VAX2012Q.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine Dose Group 8 mcg dose

VAX2012Q, 8 mcg dose

Group Type EXPERIMENTAL

VAX2012Q

Intervention Type BIOLOGICAL

Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages

Vaccine Dose Group 12 mcg dose

VAX2012Q, 12 mcg dose

Group Type EXPERIMENTAL

VAX2012Q

Intervention Type BIOLOGICAL

Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages

Control

Fluzone Quadrivalent vaccine

Group Type ACTIVE_COMPARATOR

Fluzone Quadrivalent

Intervention Type BIOLOGICAL

Fluzone Quadrivalent (Influenza Vaccine)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VAX2012Q

Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages

Intervention Type BIOLOGICAL

Fluzone Quadrivalent

Fluzone Quadrivalent (Influenza Vaccine)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Quadrivalent Recombinant Hemagglutinin Influenza Vaccine RIV4 IIV4

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females, 18-64 years of age.
* Females must be:

1. Surgically sterilized
2. Post menopausal:
* 12 months of spontaneous amenorrhea or
* 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 milli-International Units (mIU)/ml or
* 6 weeks postsurgical bilateral oophorectomy

3\. Those of childbearing potential must have a negative pre-treatment serum pregnancy test followed by a confirmatory urine pregnancy test immediately prior to vaccination and must agree to use a reliable form of contraception for at least 21 days post vaccination including contraceptives, intrauterine device, double-barrier method.
* In good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator.
* Must sign informed consent indicating understanding of the purpose of and procedures required for the study and willingness to participate.

Exclusion Criteria

* Within 6 months preceding the administration of the study vaccine, receiving any licensed or investigational vaccine.
* Within 30 days preceding the administration of the study vaccine, receiving any investigational drug.
* Excessive chronic alcohol use within the last 5 years.
* History of drug abuse, other than recreational cannabis use, within the last 5 years that could affect the subject's participation in the study.
* Significant psychiatric illness within the last 12 months which would interfere with the study.
* A chronic illness that is not medically stable, receiving a concomitant therapy in which the medication dose has not been stable for at least 3 months prior to immunization or has any other condition that could interfere with the study.
* Clinically significant abnormal liver function tests at screening: alanine transaminase (ALT) or aspartate aminotransferase (AST) \>2.5 Upper Limit of Normal (ULN).
* Total bilirubin \> 1.5 ULN if ALT or AST \> ULN or total bilirubin \> 2 ULN with ALT and AST within normal range .
* Creatinine \>1.7mg/dL, Hemoglobin \< 11g/dL for females; \<12.5 g/dL for males, white blood cells (WBC) \<2500cell/mm3 or \> 15,000cell/mm3, Platelet Count \<125,000cell/mm3
* Positive serology for HBSAg, hepatitis C virus (HCV) or HIV
* Have cancer or have received treatment for cancer within three years, excluding in situ cervical carcinoma or basal /squamous cell carcinoma of the skin at other than the vaccination site.
* Any autoimmune disease.
* Presently receiving or having a recent history of receiving (≤ six months) any medication or therapeutic modality that affects the immune system or a drug known to be frequently associated with significant major organ toxicity or system corticosteroids (oral or injectable).
* History of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component.
* Allergic to egg or egg products.
* History of Guillain-Barré Syndrome.
* Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination
* Donation of blood or blood products within 4 weeks prior to vaccination or during the 4 week study period following vaccination.
* Acute disease within 72 hours prior to vaccination.
* An oral temperature \>100.4°F (38°C) on the day of vaccination
* Body Mass Index \>40.
* Known bleeding disorders or receiving prescribed oral or parenteral anticoagulants.
* Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study or could interfere with study evaluations.

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes